COGT — Cogent Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $7.05bn
- $6.70bn
- 21
- 15
- 99
- 42
Annual cashflow statement for Cogent Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -74.8 | -72.3 | -140 | -192 | -256 |
| Depreciation | |||||
| Non-Cash Items | 43.6 | 11.3 | 20 | 25.1 | 34 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.32 | 2.02 | 0.751 | 11.4 | 11.6 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -35.9 | -58.8 | -119 | -154 | -208 |
| Capital Expenditures | 0 | -1.72 | -6.86 | -2.8 | -0.573 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 8.42 | 0 | -118 | -95 | 38.8 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 8.42 | -1.72 | -125 | -97.8 | 38.3 |
| Financing Cash Flow Items | — | -0.085 | 0 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 232 | 38 | 164 | 164 | 214 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 205 | -22.5 | -79.8 | -87.9 | 44.9 |